Black Box Warnings May Be Likely for Amgen’s Anemia Drugs, Analyst Says

Both SEC and FDA are evaluating potential safety problems with Aranesp, Amgen's blockbuster anemia treatment.  For a story from CNN, click here.  The company will participate in a meeting in May with FDA to evaluate safety issues with this type of medication.